NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp
$1.62
-0.04 (-2.41%)
At close · Sep 4
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$15.12M
Shares
9.11M
NMTC metrics
57 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$1.62
Market cap
$15.12M
Price action
19 metricsPrice change (1W)
-8.5%
Price change (30D)
+4.5%
Price change (3M)
-52.9%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
79.4%
Beta
—
RSI (14D)
37.4
Price vs SMA 50
-23.7%
Price vs SMA 200
—
Avg volume (3M)
282,848
Relative volume
0.3
Average dollar volume
$571,244
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
9.11M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.6×
reciprocal yield 62.6%
P / book
4.0
reciprocal yield 24.9%
FCF yield
-47.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-49.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-13
Profitability
9 metricsGross margin
55.6%
Operating margin
-83.4%
Trailing 12 months
Net margin
-78.6%
Gross profit (TTM)
$5.27M
Operating profit (TTM)
−$7.90M
Net income (TTM)
−$7.45M
Trailing 12 months
Diluted EPS (TTM)
$-1.01
FCF margin
-75.6%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+16.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$9.47M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+7.9%
Year over year · more shares
Revenue CAGR (3Y)
+276.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-197.6%
Return on assets
-120.4%
Debt / equity
—
Current ratio
2.8
EBITDA (TTM)
−$7.66M
Free cash flow (TTM)
−$7.16M
Quick ratio
1.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.05M
Total assets
$6.19M
Total debt
$121,896
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$7.05M
Capital expenditures (TTM)
$109,536
R&D (TTM)
$5.40M
SG&A (TTM)
$7.77M
Stock compensation (TTM)
$1.41M
R&D / revenue
57.0%
Stock compensation / revenue
14.9%
Ownership (13F)
3 metrics13F filers
26
13F filer change QoQ
-7
Institutional ownership
22.3%
Short interest
3 metricsShort interest
0.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
33 / 100
Insider activity
2 metricsNet insider buying (90D)
−$31,773
Insider-sentiment score
44 / 100
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1500198
CUSIP
64130M308
13F (30d)
21 filings
21 filers
Visit website
Investor relations